<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00860626</url>
  </required_header>
  <id_info>
    <org_study_id>interferonshorttermnucleoside</org_study_id>
    <nct_id>NCT00860626</nct_id>
  </id_info>
  <brief_title>Early Response to Interferon Combined Short-Term Nucleoside Analogue Therapy in HBeAg(+) Chronic Hepatitis B</brief_title>
  <official_title>Early Response to Interferon Combined Short-Term Nucleoside Analogue Therapy in HBeAg(+) Chronic Hepatitis B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      For HBeAg(+) patients, interferon is used for 12 weeks. On 12th week of treatment, If HBV DNA
      is undetectable (&lt;1000 copies/ml), interferon is continued alone for one year. If HBV DNA is
      still positive, nucleoside analogue is added for 3 months. After nucleoside analogue is added
      for 3 months, HBV DNA is tested again. If negative, stop nucleoside analogue and use
      interferon alone for another 6 months or longer. If HBV DNA is still positive, change to
      another nucleoside analogue or add another nucleoside analogue.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2008</start_date>
  <completion_date type="Anticipated">February 2010</completion_date>
  <primary_completion_date type="Anticipated">December 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HBeAg seroconversion rate</measure>
    <time_frame>3-6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>HBV DNA loss rate</measure>
    <time_frame>3-6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBsAg loss rate</measure>
    <time_frame>3-6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Hepatitis B, Chronic</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>At the twelfth week of interferon α treatment, HBV DNA is detectable(&gt;1000 copies/ml), or HBeAg is still positive. And nucleoside analogue is added for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>At the twelfth week of interferon α treatment, HBV DNA is detectable (&gt;1000 copies/ml), or HBeAg is still positive. But no nucleoside analogue is added.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>At the twelfth week of interferon α treatment, HBV DNA is undetectable (&lt;1000 copies/ml), or HBeAg is negative. And interferon is continued for another 9 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>interferon α plus nucleoside analogue</intervention_name>
    <description>Standard dose of interferon is used for 12 weeks. On 12th week of treatment, HBV DNA is still detectable (&gt;1000 copies/ml), or HBeAg is still positive. And lamivudine is added for 3 months. After nucleoside analogue is added for 3 months, HBV DNA is tested again. If negative, stop nucleoside analogue and use interferon alone for another 6 months or longer. If HBV DNA is still positive, change to another nucleoside analogue or add another nucleoside analogue.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>interferon α</intervention_name>
    <description>Standard dose of interferon is used for 12 weeks.On 12th week of treatment, HBV DNA is still detectable (&gt;1000 copies/ml), or HBeAg is still positive. But no nucleoside analogue is added.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>interferon α</intervention_name>
    <description>Standard dose of interferon is used for 12 weeks.On 12th week of treatment, HBV DNA is undetectable, or HBeAg is negative. And interferon is continued alone for another 9 months.</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HBsAg posive for 6 months

          -  HBeAg positive, and HBeAb negative

          -  HBV DNA&gt;1.0×E5 copies/ml

          -  ALT&gt;80 u/L within 3 months

        Exclusion Criteria:

          -  pregnant women

          -  conbination infection of HCV, HAV, or HEV

          -  conbination infection of HIV

          -  any contraindication of interferon α
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gao zhiliang, Doctor</last_name>
    <role>Study Chair</role>
    <affiliation>The Third Affliated Hospital of Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>huang zhanlian, doctor</last_name>
    <phone>+86013580584031</phone>
  </overall_contact>
  <location>
    <facility>
      <name>The Third Affliated Hospital of Sun Yat-sen University</name>
      <address>
        <city>Guang zhou</city>
        <state>Guang dong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>huang zhanlian, Doctor</last_name>
      <phone>+86013580584031</phone>
      <email>zhanlianh@21cn.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 11, 2009</study_first_submitted>
  <study_first_submitted_qc>March 11, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2009</study_first_posted>
  <last_update_submitted>March 11, 2009</last_update_submitted>
  <last_update_submitted_qc>March 11, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 12, 2009</last_update_posted>
  <responsible_party>
    <name_title>The Third Affliated Hospital of Sun Yat-sen University</name_title>
    <organization>The Third Affliated Hospital of Sun Yat-sen University</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

